ArticleEuropean journal of clinical investigation2020
Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection.
Article in European journal of clinical investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Antibody‒drug conjugates with DHODH inhibitor as novel payload class for cancer and SARS-CoV-2 infection therapies.Acta pharmaceutica Sinica. B · 2026Article
- Quinazolinones as Bioisosteres of Naphthoquinones: A Path to PotentACS medicinal chemistry letters · 2026Article
- The NovelViruses · 2022Article
- Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-Journal of medicinal chemistry · 2022Article
- Human/SARS-CoV-2 genome-scale metabolic modeling to discover potential antiviral targets for COVID-19.Journal of the Taiwan Institute of Chemical Engineers · 2022Article
- Development of accelerated high-throughput antiviral screening systems for emerging orthomyxoviruses.Antiviral research · 2022Article
- Effects of metabolic cancer therapy on tumor microenvironment.Frontiers in oncology · 2022Review
- SARS-CoV-2 Antiviral Therapy.Clinical microbiology reviews · 2021Review
- Article
- A Bioluminescent 3CLViruses · 2021Article
- Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.European journal of pharmacology · 2021Review
- The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models.Virus research · 2021Article
- The New GenerationMicroorganisms · 2021Article
- Article
- Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-Journal of medicinal chemistry · 2021Article
- Metabolism and Innate Immunity Meet at the Mitochondria.Frontiers in cell and developmental biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.